EDF Health

The Trump EPA’s “Working Approach” to new chemical reviews is only working for the chemical industry

Richard Denison, Ph.D., is a Lead Senior Scientist.

On Tuesday EDF filed detailed comments on the Environmental Protection Agency’s (EPA) “Working Approach to Making New Chemical Determinations under TSCA.”

The document is a major disappointment, to say the least.  The Trump EPA has worked very hard to render this long-awaited update of its approach to reviewing new chemicals under TSCA an empty exercise.  Despite Administrator Wheeler’s promises in January 2019 to the contrary:

  • EPA has still failed to provide any legal or scientific justification for its Working Approach.
  • EPA provided no actual response to the many detailed comments it received on its 2017 framework, instead issuing a 1.5-page document that dismisses many of the comments merely as having “stemmed from a misunderstanding of the Agency’s intent.”
  • EPA held a public meeting – but did so without first providing the Working Approach to stakeholders; EPA then limited their comments at the meeting to 2-3 minutes each and ended the meeting well ahead of schedule.
  • EPA’s new framework ignores the earlier comments it received, retaining all of the core flaws of the 2017 Framework and in fact doubling down on several of them.

Most remarkably, EPA seems to want to make clear that the Working Approach is hardly worth the paper on which it is written.  Read More »

Also posted in Health policy, Industry influence, Regulation / Tagged , , , | Comments are closed

The Trump EPA reaches a shocking new low in failing to protect workers under TSCA

Richard Denison, Ph.D., is a Lead Senior Scientist.

Just when I thought EPA putting workers’ health at risk by shirking its responsibilities under the Toxic Substances Control Act (TSCA) couldn’t get any worse, it has.[pullquote]The notion that worker protection can or should be relegated to the equivalent of a shock avoidance experiment is deeply offensive if not outright immoral.[/pullquote]

In its risk evaluations of existing chemicals (see our comments here and here) and its reviews of  new chemicals (see our comments here) entering the market, EPA has found ways bordering on the diabolical to avoid identifying or to understate the extent and nature of risks to workers making or using those chemicals.  The agency:

  • Simply assumes without evidence that workers will wear fully effective personal protective equipment (respirators and gloves).
  • Distorts OSHA regulations and claims they apply where they don’t.
  • Treats voluntary instruments that impose no binding requirements as if they were mandatory.
  • Assumes that if the average worker’s exposure does not exceed its acceptable risk level, then it doesn’t matter if there are exceedances for those workers most highly exposed.
  • Has unquestioningly accepted and used manufacturers’ undocumented data on workplace exposure levels even when data from more authoritative sources show far higher exposures.
  • And has adopted a cancer risk benchmark that is as much as two orders of magnitude more permissive of risk than warranted under TSCA.

All this despite TSCA’s express identification of workers as a “potentially exposed or susceptible subpopulation” that warrants special protection.

As appalling as all of this is, it just got worse. Read More »

Also posted in Health policy, Industry influence / Tagged , | Comments are closed

EPA still has a very long way to go on transparency under TSCA

Richard Denison, Ph.D., is a Lead Senior Scientist.

EPA recently held a public meeting where it unveiled its first set of confidential business information (CBI) claim “determinations.”  These came three and half years after updates to the Toxic Substances Control Act (TSCA) required EPA to review CBI claims and publicly state the basis for its decision to approve or deny each claim.  EPA also recently finally started assigning “unique identifiers” to chemicals where it approves a claim to hide the chemical’s identity from the public.  These identifiers also come very late, having been called for starting immediately under the 2016 reforms to TSCA.

EPA also recently began posting to its ChemView database premanufacturing notices (PMNs) it receives on new chemicals, as well as some of the documents it generates when reviewing new chemicals (though these are exceedingly hard to find).

These and a few other modest recent improvements are certainly better late than never.  Their slowness in arriving, however, is a stark illustration of the far greater priority the Trump EPA has given to favoring the chemical industry’s interests over the public interest.

Moreover, EDF’s examination of these recent measures reveals both how far behind EPA still is in meeting TSCA’s mandates to provide chemical information to the public, and that EPA is failing to comply with a number of those mandates.

Last Friday EDF filed comments with EPA detailing both the shortcomings in what EPA has done and what it has failed to do.  We also provided a host of recommendations for improvements to the EPA websites and databases that are critical if they are to meet the public’s right to know about chemicals and EPA’s review of them under TSCA.  This post will summarize some of the key findings detailed in our comments.  Here is a list of topics covered in our comments and, more briefly, in this post:

Read More »

Also posted in Health policy / Tagged , , , | Comments are closed

What connects cross country skiing and chemical safety?

Sam Lovell, Project Manager.

An idyllic afternoon gliding through fresh snow may seem as far removed as you can get from Washington, D.C. decision-making about toxic chemicals. However, as recently reported by Outside Magazine, there’s an intriguing connection here that ought to give skiers, and the rest of us, some pause.

Last year, the Environmental Protection Agency (EPA) approved a new chemical for use in ski wax. Just a few months before, the agency had planned to deny the chemical market entry based on the concern, among others, that exposure could “waterproof the lungs” – causing severe, acute harm. Due to the abrupt reversal in EPA’s decision, EDF began looking further into this case and made public records and Freedom of Information Act requests.

The intervening steps that resulted in this chemical getting the green light to market reveal serious problems in EPA’s new chemicals program regarding transparency and industry influence.

Read More »

Also posted in Health policy, Industry influence, PFAS / Tagged , , | Comments are closed

Finally something we can (mostly) commend EPA for doing under TSCA

Richard Denison, Ph.D., is a Lead Senior Scientist.

Readers of this blog will know how concerned EDF is with ensuring the public’s right to know about chemicals to which they may be exposed.  We have repeatedly sounded the alarm when EPA has taken steps to deny public access to chemical information, whether for chemicals entering the market or those already in commerce.  Even in recent months, EPA has sided with chemical companies in denying access to health and safety information on chemicals EPA is assessing under the Toxic Substances Control Act (TSCA).

So we were pleasantly surprised by a letter to an industry group that EPA posted on Friday.  Read More »

Also posted in Health policy, Industry influence, Regulation / Tagged , | Comments are closed

The Trump EPA says “precede” means “follow”

Richard Denison, Ph.D., is a Lead Senior Scientist.

[Corrections added below in bracketed italics on 1-17-20]

Last month EPA finally released its long-awaited update to its controversial 2017 New Chemicals Decision-Making Framework, which describes how EPA is conducting risk reviews of new chemicals under the Toxic Substances Control Act (TSCA).  While we are still reviewing it and will be filing comments, it is clear the new document suffers from many of the same problems as the prior version, as well as raising additional concerns.

A core problem of both documents is EPA’s illegal bifurcation of its treatment of a new chemical’s “intended” conditions of use – those proposed by the company submitting a premanufacture notification (PMN) to EPA – from the chemical’s “reasonably foreseen” conditions of use.  EPA does so despite TSCA’s clear instruction that EPA address potential risks from both categories in an integrated manner and at the same time.  EPA’s frameworks instead relegate any consideration of “reasonably foreseen” conditions of use to a separate, later process undertaken upon receipt of a separate notification submitted to EPA in response to a Significant New Use Rule (SNUR) – assuming EPA has actually promulgated a final SNUR for the chemical in question.

EPA has now used this bifurcated approach to greenlight hundreds of new chemicals for market entry – finding that they are “not likely to present an unreasonable risk” based on a review only of the chemicals’ intended conditions of use.  EDF has blogged in detail about the inadequacies of EPA’s “SNUR-only approach” and the disturbing extent of its application.

EPA has yet to provide any legal justification for its approach – how it believes the approach comports with TSCA – let alone demonstrate how it provides for protection of health and the environment despite deviating from what Congress intended EPA do under the law.

[pullquote]How on earth can EPA assert with a straight face that it is promulgating SNURs that precede its “not likely” determinations?[/pullquote]While we will have much more to say on the new framework, in the remainder of this post I want to focus on EPA’s characterization of its reliance on the SNUR-only approach.  EPA now says it has expanded that approach to two different scenarios:  One is “SNURs that Precede “Not Likely” Determinations” and the other is “SNURs that Follow “Not Likely” Determinations.”

We have examined the accuracy of EPA’s claim that the first type of SNUR precedes EPA’s “Not Likely” determination for a given new chemical.  The timing is critical here:  If there is a significant lag between EPA’s “Not Likely” determination and the issuance of a SNUR, all kinds of problems arise, which we have discussed previously.  To name two:

  • If a company engages in what EPA plans to deem a “significant new use” during the gap between the determination and at least proposal of a SNUR, then EPA cannot subject that use to the notification requirements of the SNUR because the use is “ongoing” and no longer “new.” That includes a new use engaged in by the company that got a green light for its chemical based on EPA’s review of only its intended conditions of use.
  • Such a company that wants to have the ability to engage in uses beyond those it said it initially intended would have serious incentives to seek to avoid having EPA issue the SNUR. Because SNURs are done through rulemaking, the company can urge EPA to block or modify the SNUR through the rulemaking process.  It can also apply pressure on EPA not to pursue a SNUR at all.

So is EPA being accurate when it claims that a large number of its SNURs precede EPA’s “Not Likely” determination for those same new chemicals?

The answer is a resounding no:  Read More »

Also posted in Health policy, Industry influence, Regulation / Tagged , , | Comments are closed